" "

Nestle India and Dr Reddy's Laboratories forge JV to innovate in nutraceuticals

Sumit Vishwakarma
New Update
Nestle India and Dr Reddy's Laboratories forge JV

Nestle India and Dr Reddy's Laboratories Ltd have announced their partnership to form a joint venture (JV) aimed at delivering innovative nutraceutical products to the Indian market and other agreed areas.

The JV will focus on bringing a range of nutritional health solutions and supplements backed by the expertise of both companies in their respective fields.

What products will be offered?

The partnership will introduce a variety of products that cater to different health needs, including metabolic support, hospital nutrition, general wellness, women's health, and child nutrition.


The JV will feature well-known brands like Nature’s Bounty, Osteo Bi-Flex, and Ester-C from Nestle Health Science (NHSc) and products such as Rebalanz and Celevida from Dr Reddy’s.

Strategic benefits of the JV

According to Suresh Narayanan, Chairman and Managing Director at Nestlé India, this joint venture is set to enhance the availability and distribution of high-quality nutritional products across India. Narayanan highlighted Dr Reddy’s strength in the pharmaceutical sector and their shared commitment to improving consumer health. 

"This joint venture will enable us to build a robust retail and distribution network to take our brands closer to consumers and making a meaningful difference to improve the quality of life," he stated.

Expected outcomes for consumers

M V Ramana, CEO of Branded Markets (India & Emerging Markets), Dr Reddy, said, "This joint venture is a novel approach by two companies that have a shared purpose of good health. We are pleased to partner with Nestlé India to bring innovations from the Nestlé Health Science global portfolio to consumers in India. This novel approach of leveraging mutually complementary strengths of both parent companies will enable better access and affordability for consumers."

The joint venture is scheduled to become operational in the second quarter of fiscal year 2025.